

ADVANCE: WHY AND WHAT?

VINCENT BAUCHAU


GSK VACCINES
EFPIA LEAD ADVANCE

6 MARCH 2019



ADVANCE

Measles, February 2009






ADVANCE

H1N1, June 2009

New Influenza A (H1N1),
Number of laboratory confirmed cases as reported to WHO

Status as of 08 June 2009
06:00 GMT



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

Map produced: 08 June 2009 06:30 GMT

Data Source: World Health Organization
Map Production: Public Health Information
and Geographic Information Systems (GIS)
World Health Organization



© WHO 2009. All rights reserved




ADVANCE

Global threat in a fragmented landscape



ADVANCE

EUROPE IS COMPLEX





European Medicines Agency
Post-authorisation Evaluation of Medicines for Human Use

London, 25 September 2009
Doc. Ref: EMEA/359381/2009


**CHMP Recommendations for the Pharmacovigilance Plan as part of the
Risk Management Plan to be submitted with the Marketing Authorisation
Application for a Pandemic Influenza Vaccine**

Adopted by CHMP in November 2006
Revision 1.0 adopted by CHMP on 25 June 2009

Revision 1.1 adopted by CHMP on 24 September 2009




ADVANCE





ADVANCE





ADVANCE

Fragmentation or opportunities ?

A long journey ...



ADVANCE



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

10 September 2010
EMA/481508/2010

Vaccines and Health Outcomes in Europe
Research Gaps

confluence of interest
rather than
conflicts of interests



ADVANCE



Innovative Medicines Initiative

IMI 7th Call for proposals 2012

Developing a Framework for Rapid Assessment of Vaccination Benefit/Risk in Europe




*An efficient and sustainable infrastructure
for rapid and integrated monitoring of post-
approval benefit/risk of vaccines under clear
governance rules meeting the common
interest of all main stakeholders*

IMI Call, July 2012



ADVANCE



IMI Call, July 2012



Vaccine

journal homepage: www.elsevier.com/locate/vaccine

Review

The ADVANCE Code of Conduct for collaborative vaccine studies

Xavier Kurz^{a,*}, Vincent Bauchau^b, Patrick Mahy^c, Steffen Glismann^d, Lieke Maria van der Aa
François Simondon^e, for the ADVANCE consortium¹

^a Surveillance & Epidemiology, European Medicines Agency, London, United Kingdom

^b Vaccine Clinical Safety and Pharmacovigilance, GSK Vaccines, Wavre, Belgium

^c Scientific Institute of Public Health, Brussels, Belgium

^d Scientific Affairs & Public Health, Paediatric Vaccines Europe, GSK Vaccines, Wavre, Belgium

^e Institut de recherche pour le développement (IRD), Paris, France

Diversity: the art of thinking independently together

Malcom Forbes